Compare EM & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EM | OABI |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | China | United States |
| Employees | N/A | 114 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 289.1M | 253.4M |
| IPO Year | 2021 | N/A |
| Metric | EM | OABI |
|---|---|---|
| Price | $1.11 | $1.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $1.25 | ★ $6.67 |
| AVG Volume (30 Days) | 51.5K | ★ 272.5K |
| Earning Date | 04-27-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.30 | $52.42 |
| Revenue Next Year | $5.26 | $64.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.01 | $1.22 |
| 52 Week High | $1.46 | $2.49 |
| Indicator | EM | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 35.82 | 45.35 |
| Support Level | $1.10 | $1.71 |
| Resistance Level | $1.18 | $1.89 |
| Average True Range (ATR) | 0.01 | 0.12 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 14.49 |
Smart Share Global Ltd is a consumer tech company providing mobile device charging services through an extensive online and offline network in China. It provides service through power banks, placed in POIs operated by location partners, such as entertainment venues, restaurants, shopping centers, hotels, transportation hubs, and public spaces. Geographically, the company generates revenue from the PRC. The company has two segments, the mobile device charging segment and the PV business segment. The company generates the majority of its revenue from the mobile device charging segment.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.